Protagonist Therapeutics, Inc. (PTGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$145.72-2.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PTGX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On August 5, 2026, Protagonist Therapeutics, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2026. A copy of the press release titled “Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update” is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The filing is about the adoption of a new equity incentive plan and does not involve any changes in management or board composition.
Results of Operations and Financial Condition. On May 5, 2026, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended March 31, 2026. A copy of the press release titled “Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On February 25, 2026, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release titled “Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On November 6, 2025, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended September 30, 2025. A copy of the press release titled “Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On August 6, 2025, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2025. A copy of the press release titled “Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On May 6, 2025, Protagonist Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2025. A copy of the press release titled “Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant to
Other Information. On March 17, 2025, Protagonist Therapeutics, Inc. (the “Company”) and Takeda Pharmaceuticals USA, Inc. (“Takeda”) agreed, pursuant to the provisions of the parties’ License and Collaboration Agreement dated January 31, 2024, as amended, that Takeda will assume responsibility for leading and implementing the regulatory strategy and associated activities for preparation of the New Drug Application related to rusfertide in polycythemia vera to be submitted with the United Stat…
Results of Operations and Financial Condition. On February 21, 2025, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release titled “Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update” is furnished pursuant to
Chief Development Officer — Suneel Gupta: The filing describes an internal title change from Chief Development Officer to Executive Vice President, Clinical Development, which is a role expansion rather than a departure.
Entry into a Material Definitive Agreement On November 13, 2024, Protagonist Therapeutics, Inc. (the “ Company ”) and Janssen Biotech, Inc., a Pennsylvania corporation (“ Janssen ”) entered into an amendment (the “ Amendment ”) to their amended and restated License and Collaboration Agreement dated July 27, 2021 (the “ Collaboration Agreement ”). The Amendment: (a) increases the milestone payment set forth in Section 7.3.1(D) (for a Phase 3 clinical trial for any Licensed Product for any indi…
Results of Operations and Financial Condition. On November 7, 2024, Protagonist Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2024. A copy of the press release titled “Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update” is furnished pursuant to
Director — Daniel N. Swisher Jr.: A board member resigned from the board and audit committee, but the event is low materiality as he continues as an advisor and no disagreement was reported.
Results of Operations and Financial Condition. On August 6, 2024, Protagonist Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2024. A copy of the press release titled “Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On May 7, 2024, Protagonist Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2024. A copy of the press release titled “Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update” is furnished pursuant to
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.